Published: Mar 11, 2021
LONDON, March 11, 2021 (GLOBE NEWSWIRE) Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, announced today the appointment of Colin A. Love, PhD, to its Board of Directors with immediate effect. Dr. Love has over 30 years of experience leading biopharmaceutical company operations, including the development and launch of several biotechnology products.
“We are delighted to welcome Colin Love to Freeline’s Board of Directors,” said Theresa Heggie, Chief Executive Officer of Freeline. “His appointment comes at a key time as Freeline evolves into its next stage of growth, including the development, production and potential commercialization of the Company’s pipeline. Colin’s extensive experience in manufacturing complex biotechnology products will be valuable
Kumpulan Lagu Grup Band Malaysia UK S, Di Sana Menanti Di Sini Menunggu Sangat Populer tribunnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tribunnews.com Daily Mail and Mail on Sunday newspapers.